Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer

Figure 1 Main acquired resistance mutations detected by liquid biopsy. Key acquired resistance mutations are associated with the epidermal growth factor receptor (EGFR) pathway. Other mutations or amplifications in tyrosine kinase receptors, such as HER2/ERBB2 or MET, can potentially lead to resistance to anti-EGFR therapy. ¹Indicate acquired resistance mutations, as reported in previous studies. EGFR: Epidermal growth factor receptor.